Results 11 to 20 of about 2,751,693 (208)

Management of Imatinib-Resistant CML Patients [PDF]

open access: yesOncology Research and Treatment, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option. Although imatinib is highly effective and well tolerated, the development of resistance represents a clinical challenge.
Linke, Rolf, Dempke, Wolfram
openaire   +5 more sources

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]

open access: yes, 2011
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C(
Iqbal, Zafar   +4 more
core   +13 more sources

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report [PDF]

open access: yesBiological Procedures Online, 2004
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance.
Iqbal Zafar   +2 more
doaj   +2 more sources

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance [PDF]

open access: yesJournal of Hematology & Oncology, 2011
Background The BCR-ABL1 translocation occurs in chronic myeloid leukemia (CML) and in 25% of cases with acute lymphoblastic leukemia (ALL). The advent of tyrosine kinase inhibitors (TKI) has fundamentally changed the treatment of CML.
Zaborski Margarete   +4 more
doaj   +2 more sources

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

open access: yesBiologics: Targets & Therapy, 2009
Radhakrishnan Ramchandren, Charles A SchifferDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML ...
Radhakrishnan Ramchandren   +1 more
doaj   +1 more source

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia [PDF]

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2011
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing ...
Roberta Bitencourt   +2 more
doaj   +5 more sources

V280G Mutation, Potential Role in Imatinib Resistance: First Case Report

open access: yesClinical Medicine Insights: Oncology, 2017
Introduction: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction ...
Ana P Azevedo   +5 more
doaj   +2 more sources

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

open access: yesMolecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu   +8 more
doaj   +1 more source

SRCircumventing imatinib resistance [PDF]

open access: yesCancer Cell, 2004
The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses.
Deininger, Michael W.N.   +1 more
openaire   +2 more sources

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. [PDF]

open access: yesInt J Mol Sci, 2022
Chronic myeloid leukemia (CML) is a hematologic disorder characterized by the oncogene BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, performs exceptionally well with minimal toxicity
Prado-Carrillo O   +6 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy